Rozzini Luca, Chilovi Barbara Vicini, Bertoletti Erik, Conti Marta, Delrio Ilenia, Trabucchi Marco, Padovani Alessandro
Department of Neurology, University of Brescia, Italy.
Am J Alzheimers Dis Other Demen. 2007 Feb-Mar;22(1):42-7. doi: 10.1177/1533317506297517.
Cholinesterase inhibitors (ChEIs) are effective in improving cognition and behavior in patients affected by Alzheimer's disease (AD) as well as by Lewy bodies dementia (DLB). The authors compared the effect of rivastigmine in the treatment of cognitive impairment and behavioral and psychological symptoms of dementia (BPSD) in 30 AD and in 30 DLB patients. At baseline, DLB compared to AD patients showed a greater number of extrapyramidal symptoms (P < .005) and were similar regarding cognitive symptoms and BPSD. After treatment, both groups showed a comparable cognitive and psycho-behavioral improvement. A significant difference between AD and DLB patients was found for hallucinations (P < .002). Rivastigmine produces comparable cognitive benefits in patients with DLB and AD and also a significant improvement of behavioral disorders. These findings support the view that ChEIs should be considered a first-line treatment of the cognitive and psycho-behavioral symptoms of both AD and DLB.
胆碱酯酶抑制剂（ChEIs）对改善受阿尔茨海默病（AD）以及路易体痴呆（DLB）影响的患者的认知和行为有效。作者比较了30例AD患者和30例DLB患者中卡巴拉汀治疗认知障碍以及痴呆的行为和心理症状（BPSD）的效果。在基线时，与AD患者相比，DLB患者表现出更多的锥体外系症状（P <.005），在认知症状和BPSD方面相似。治疗后，两组在认知和心理行为方面均有可比的改善。AD和DLB患者在幻觉方面存在显著差异（P <.002）。卡巴拉汀在DLB和AD患者中产生可比的认知益处，并且对行为障碍也有显著改善。这些发现支持以下观点，即ChEIs应被视为AD和DLB认知及心理行为症状的一线治疗方法。
